Clinical trial · Interventional
Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer
Paclitaxel Plus Carboplatin (TC) Versus TC Plus Endostar in Patients With Advanced Non-small Cell Lung Cancer(NSCLC): a Randomized, Double-blind, Placebo-controlled, Multicentre Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this randomized, double-blind, placebo-controlled, multicentre trial, 126 patients between July 5, 2007 and July 30, 2008 were enrolled from 10 centers. The leader units are Shanghai Chest Hospital Affiliated to Shanghai Jiao-Tong University and Shanghai Changzheng Hospital. All eligible patients received 1 cycle (21 days) of TC chemotherapy. After chemotherapy, patients evaluated as SD (Stable Disease) or above were randomized to receive endostar plus TC or TC alone for 3 cycles, 21 days as one cycle.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endostar(Recombinant Human Endostatin Injection) | Drug | — | UNRESOLVED |
| paclitaxel-carboplatin | Drug | Carboplatin/Paclitaxel Regimen | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- The control group
- description
- paclitaxel-carboplatin
- interventionNames
- Drug: paclitaxel-carboplatin
- type
- EXPERIMENTAL
- label
- The treatment group
- description
- paclitaxel-carboplatin plus Endostar
- interventionNames
- Drug: Endostar(Recombinant Human Endostatin Injection)
- Drug: paclitaxel-carboplatin
Primary outcomes (1)
- measure
- Progression-free Survival (PFS)
- timeFrame
- every 2 months until disease progression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * histologically or cytologically confirmed, previously untreated stage IIIB or IV NSCLC * age of 18-75 years * at least one measurable lesion (RECIST) * patients evaluated as SD or above after 1 cycle (21 days) of TC chemotherapy . * adequate hematologic, cardiac, renal, and hepatic function * ECOG PS 0-2 Exclusion Criteria: * symptomatic brain metastases * bone metastases with complications * major organ dysfunction * bleeding diathesis or coagulopathy * pregnant or lactating woman
References
Publications (0)
Data not yet available